Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prolgolimab - Biocad

Next Previous
Drug Profile

Prolgolimab - Biocad

Alternative Names: Anti PD-1 mAb; Anti-PD-1 monoclonal antibody; BCD-100 - Biocad; Forteca

Latest Information Update: 04 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocad
  • Developer Biocad; Pavlov First State Medical University of Saint Petersburg; SPH-BIOCAD
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Malignant melanoma
  • Phase III Cervical cancer; Non-small cell lung cancer
  • Phase II Hodgkin's disease
  • No development reported Solid tumours

Most Recent Events

  • 02 Jun 2023 Interim safety and efficacy data from a phase II CAESURA trial presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 10 Mar 2023 Phase-II clinical trials in Hodgkin's disease (Combination therapy, In adults, In the elderly, Second-line therapy or greater) in Russia (IV) (NCT05757466)
  • 10 Mar 2023 Phase-II clinical trials in Hodgkin's disease (Second-line therapy or greater, Monotherapy, In adults, In the elderly) in Russia (IV) (NCT05757466)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top